Data on Biomolecular Screening Reported by Researchers at Novartis Pharma (Fluorescence Lifetime-Based Competitive Binding Assays for Measuring the Binding Potency of Protease Inhibitors In Vitro)
The news reporters obtained a quote from the research from Novartis Pharma, "Here we report the development of competitive binding assays as novel, inhibitor-centric assays, principally employing the FLT of the acridone dye Puretime 14 (PT14) as the readout parameter. Exemplified with two case studies on human serine proteases, the details of the rationale for both the design and synthesis of probes (i.e., active site-directed low-molecular-weight inhibitors conjugated to PT14) are provided."
According to the news reporters, the research concluded: "Data obtained from testing inhibitors with the novel assay format match those obtained with alternative formats such as FLT-based protease activity and time-resolved fluorescence resonance energy transfer-based competitive binding assays."
For more information on this research see: Fluorescence Lifetime-Based Competitive Binding Assays for Measuring the Binding Potency of Protease Inhibitors In Vitro.
Our news correspondents report that additional information may be obtained by contacting A. Boettcher,
Keywords for this news article include:
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC
Most Popular Stories
- PBS Series Examines America's Demographic Shift
- Tim Cook Has Proved That Apple is His Baby
- Royals Beat A's in 12-inning Wild Card Thriller
- Construction Spending Down Again for August
- Texas Sees Gains in Hispanic College Enrollment
- Americans Bet Big on Gambling Industry
- California's Ban on Plastic Bags: What Now?
- Petri Likely Broke House Ethics Rules
- Exxon Gives Nod to Fracking Risks
- Morgan: 'Can't Believe' Wal-Mart Blaming Him